摘要
目的：观察３例人肝癌组织细胞与其自体激活Ｂ淋巴细胞融合后融合细胞表面分子ＧＰ７５和免疫相关分子ＭＨＣⅠ、ＭＨＣⅡ和Ｂ７的表达情况，以便为肿瘤疫苗向临床试验过渡提供人体细胞的实验依据。方法：应用聚乙二醇（ＰＥＧ）法将人肝癌细胞与其自体激活Ｂ淋巴细胞融合，利用流式细胞仪观察融合细胞表面分子ＧＰ７５和免疫相关分子ＭＨＣⅠ、ＭＨＣⅡ和Ｂ７的表达情况。结果：融合细胞表面不仅表达肝癌细胞表面的ＧＰ７５分子，还可表达共刺激分子Ｂ７及ＭＨＣⅠ、ＭＨＣⅡ。结论：人肝癌细胞与其自体激活的Ｂ淋巴细胞融合后的杂交瘤细胞既能表达肝癌细胞表面分子ＧＰ７５，又可表达共刺激信号分子。
Objective: To observe the expression of the GP75, MHCⅠ, MHCⅡ and B7 molecules on the surface of hybrid cells generated by fusion of human hepatocellular carcinoma cells (HCC) with auto logous activated B cells of 3 cases of HCC patients. Methods: Human hepatocellular carcinoma cells were fused with activated B cells by treatment with polyethylene glycol (PEG), and the expression of GP75, MHCⅠ, MHCⅡ and B7 molecules on the surface of hybrid cells was determined by flow cytometry. Results: The hybrid cells were able to express not only GP75 molecules of human HCC cells, but also MHCⅠ, MHCⅡ and B7 of B cells. Conclusion: The above results indicated that this kind of human fusion cells could be used as a positive and specific immune therapy in clinical trials against HCC someday.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
1998年第6期507-510,共4页
Academic Journal of Second Military Medical University
基金
国家自然科学基金
国家杰出青年科学基金
上海市卫生局医学领先学科资助
关键词
肿瘤疫苗
肝肿瘤
B细胞
细胞融合
tumor vaccine
liver neoplasms
B lymphocyte
cell fusion
